<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR50">
 <label>50.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yao</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Ye</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Cui</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Niu</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Dong</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Song</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Zhan</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Tan</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>D</given-names>
   </name>
  </person-group>
  <article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title>
  <source>Clin Infect Dis</source>
  <year>2020</year>
  <volume>71</volume>
  <fpage>732</fpage>
  <lpage>739</lpage>
  <?supplied-pmid 32150618?>
  <pub-id pub-id-type="pmid">32150618</pub-id>
 </element-citation>
</ref>
